Treatment of Cutaneous Ulcers With a Novel Biological Dressing

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Québec, CHU de Québec
ClinicalTrials.gov Identifier:
NCT00207818
First received: September 13, 2005
Last updated: February 10, 2014
Last verified: February 2014
  Purpose

The aim of the study is to evaluate the effect of a biological dressing on the healing process of venous ulcers. The dressing is a reconstructed skin substitute made with the patients own cells.


Condition Intervention Phase
Venous Ulcers
Device: self assembled skin substitute (SASS)
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Treatment of Cutaneous Ulcers With a Novel Biological Dressing

Further study details as provided by Centre Hospitalier Universitaire de Québec, CHU de Québec:

Primary Outcome Measures:
  • wound closure [ Designated as safety issue: No ]
    -


Secondary Outcome Measures:
  • % of healing at 6 months of treatment [ Designated as safety issue: No ]
    -


Enrollment: 6
Study Start Date: September 1999
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: self assembled skin substitute (SASS)
    Wound care with self assembled skin substitute (SASS)
Detailed Description:

The hypothesis of this trial is that the cutaneous model SASS, a dermal epidermal skin substitute, created by the LOEX could be as high-performant, or even better, than the one's already existent in North America for the wound care. We anticipate showing on 6 patients that ulcer that did not close with conventional treatment, will heal or at least improve with this treatment.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men or women from 18 to 85 years old
  2. Have a venous ulcer or a mixed ulcer

Exclusion Criteria:

Diabetes Mental deficiency Hepatitis holder (A-B-C) HIV positive Pregnancy or lactation Corticosteroids therapy Radiotherapy Chemotherapy

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00207818

Locations
Canada
Centre hospitalier affilie universitaire de Quebec
Quebec, Canada, G1J 1Z4
Sponsors and Collaborators
Centre Hospitalier Universitaire de Québec, CHU de Québec
Investigators
Principal Investigator: Francois A Auger, MD Centre hospitalier affilié universitaire de Québec
Study Director: Lucie Germain, Ph.D. Centre hospitalier affilié universitaire de Québec
  More Information

Additional Information:
Publications:
Responsible Party: Centre Hospitalier Universitaire de Québec, CHU de Québec
ClinicalTrials.gov Identifier: NCT00207818     History of Changes
Other Study ID Numbers: LOEX 005, 29478 Health Canada
Study First Received: September 13, 2005
Last Updated: February 10, 2014
Health Authority: Canada: Health Canada

Keywords provided by Centre Hospitalier Universitaire de Québec, CHU de Québec:
tissue engineered wound dressing; autologous skin substitute; biological dressing; wound care

Additional relevant MeSH terms:
Skin Ulcer
Ulcer
Varicose Ulcer
Cardiovascular Diseases
Leg Ulcer
Pathologic Processes
Skin Diseases
Varicose Veins
Vascular Diseases

ClinicalTrials.gov processed this record on October 23, 2014